Know Cancer

forgot password

Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma

Phase 3
18 Years
Not Enrolling
Sarcoma, Kaposi, HIV Infections

Thank you

Trial Information

Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma

Patients receive DOX-SL every 3 weeks for a maximum of 20 cycles (including any cycles from
a previous DOX-SL study). KS lesions are evaluated prior to administration of each
treatment, at the end of the final treatment cycle, and at 4 weeks following the end of the
final treatment. Patients who respond will be followed every 2 months for up to 1 year.
Study treatment may be interrupted for up to 4 months because of complete response,
development of opportunistic infections, or adverse drug effects.

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:


- Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy
provided these doses have been stable for at least 1 month.

- Maintenance therapy for tuberculosis, fungal, and herpes infections.

- Therapy for new episodes of tuberculosis, fungal, and herpes infections except with
potentially myelotoxic chemotherapy.

- Foscarnet or ganciclovir for CMV infection.

- Colony stimulating factors and erythropoietin.

Patients must have:

- Moderate to severe AIDS-related Kaposi's sarcoma.

- Documented anti-HIV antibody.

- No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma,
Pneumocystis carinii, or other microorganisms (if under treatment with myelotoxic


- Eligible KS patients include those who have discontinued therapy in the control arm
of a DOX-SL KS study because of side effects or inadequate efficacy OR other KS
patients for whom DOX-SL is believed to be indicated. Patients must not be eligible
for other Liposome Technology protocols comparing DOX-SL with established therapies.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Clinically significant cardiac disease.

- Confusion or disorientation.

Concurrent Medication:


- Other cytotoxic cancer chemotherapy.

Patients with the following prior conditions are excluded:

- Prior neoplasms treated with extensive chemotherapy that, in the investigator's
opinion, has led to an irreversibly compromised marrow function.

- History of idiosyncratic or allergic reaction to anthracyclines.

- History of major psychiatric illness.

Prior Medication:

Excluded within the past 4 weeks:

- Cytotoxic chemotherapy (other than in a qualifying Liposome Technology protocol).

- Interferon treatment.

Prior Treatment:

Excluded within the past 3 weeks:

- Radiation or electron beam therapy.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

Completion Date:

Related Keywords:

  • Sarcoma, Kaposi
  • HIV Infections
  • Sarcoma, Kaposi
  • Liposomes
  • Doxorubicin
  • Acquired Immunodeficiency Syndrome
  • Drug Carriers
  • HIV Infections
  • Acquired Immunodeficiency Syndrome
  • Sarcoma, Kaposi
  • AIDS-Related Opportunistic Infections
  • Sarcoma



Mem Sloan - Kettering Cancer CtrNew York, New York  10021
Saint Luke's - Roosevelt Hosp CtrNew York, New York  10025
Univ of Miami School of MedicineMiami, Florida  331361013
Mount Sinai Med CtrNew York, New York  10029
Henry Ford HospDetroit, Michigan  48202
Washington UnivSt Louis, Missouri  63108
Baylor College of MedicineHouston, Texas  77030
New York Univ Med CtrNew York, New York  10016
San Francisco Veterans Administration Med CtrSan Francisco, California  94121
East Bay AIDS CtrBerkeley, California  94705
Twelve Oaks HospHouston, Texas  77074
Virginia Mason Research Center / Clinical Trial UnitSeattle, Washington  98101
H Lee Moffit Cancer Ctr and Research InstituteTampa, Florida  33612
Saint Vincent's Hosp and Med CtrNew York, New York  10011
Pacific Oaks Med GroupBeverly Hills, California  90211
Hematology - Oncology Med Group of San Fernando ValleyEncino, California  91436
Dr Becky MillerLos Angeles, California  90048
Apogee Med GroupSan Diego, California  92103
Kaiser Permanente Med CtrSan Francisco, California  94115
UCSFSan Francisco, California  941430324
UCSF - San Francisco Gen HospSan Francisco, California  94110
Dr Mahmoud MustafaWashington, District of Columbia  20037
American Med Research InstituteAtlanta, Georgia  30329
Infectious Disease Rsch Consortium of GA / SE Clin ResourcesAtlanta, Georgia  30345
Rush Presbyterian Med CollegeChicago, Illinois  60612
Illinois Masonic Med Ctr / The Cancer CtrChicago, Illinois  60657
Northwestern Med Faculty FoundationChicago, Illinois  60611
Roswell Park Cancer InstituteBuffalo, New York  14263
Graduate Hosp / Tuttleman Cancer CtrPhiladelphia, Pennsylvania  19146
Comprehensive Care CtrDallas, Texas  75235
Houston Immunological InstituteHouston, Texas  77054